Thermo Fisher Scientific INC Form 4 insider transactions

Thermo Fisher Scientific Executive Vice President Michael D. Shafer exercised stock options and subsequently sold 10,725 shares of common stock for $600 per share.

Thermo Fisher Scientific's Senior VP and CFO, Stephen Williamson, reported a gift of 433 shares of common stock under a Rule 10b5-1 plan.

Thermo Fisher Scientific's Senior VP and Chief HR Officer, Lisa P. Britt, filed a Form 4 disclosing a planned sale of 1,057.577 shares of common stock on November 12, 2025, at a price of $588.265 per share.

Thermo Fisher Scientific's Executive Vice President and COO, Michel Lagarde, exercised stock options and subsequently sold an equal number of common shares.

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti sold shares after exercising stock options under a pre-arranged trading plan.

Lisa P. Britt, Thermo Fisher Scientific's Sr. VP and Chief HR Officer, sold common stock following the exercise of options under a Rule 10b5-1 plan.

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti sold 400 shares of common stock for $574.15 per share as part of a pre-arranged trading plan.

Thermo Fisher Scientific Inc.'s Chairman and CEO, Marc N. Casper, exercised stock options and subsequently sold shares totaling 24,354, all under a pre-arranged 10b5-1 trading plan.

Thermo Fisher Scientific Director Dion J. Weisler acquired 80.78 phantom stock units valued at $464.24 each through a deferred compensation plan, increasing his beneficial ownership.

Thermo Fisher Scientific director Scott M. Sperling acquired 91.55 phantom stock units valued at $464.24 each as part of a deferred compensation plan.

Thermo Fisher Scientific Director R. Alexandra Keith acquired 67.31 phantom stock units through the company's deferred compensation plan, increasing her beneficial ownership.

Thermo Fisher Scientific Director Karen S. Lynch acquired 67.31 phantom stock units through the company's deferred compensation plan.

Thermo Fisher Scientific Director Jennifer M. Johnson acquired 67.31 phantom stock units through a deferred compensation plan.

Thermo Fisher Scientific's Chairman and CEO, Marc N. Casper, executed pre-planned stock option exercises and subsequent sales of common stock.

Thermo Fisher Scientific's Chairman and CEO, Marc N. Casper, reported the disposition of common stock to cover tax liabilities.

Thermo Fisher Scientific's Sr. VP and CFO, Stephen Williamson, reported the disposition of common stock shares to cover tax obligations.

Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported the disposition of common stock to cover tax liabilities on August 28, 2025.

Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific Inc., disposed of common stock to cover tax liabilities.

Thermo Fisher Scientific's Executive Vice President and COO, Michel Lagarde, disposed of 961.203 shares of common stock to cover tax liabilities.

Joseph R. Holmes, VP & Chief Accounting Officer at Thermo Fisher Scientific, reported multiple stock transactions including option exercises and sales.

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti disposed of 814.702 shares of common stock at $489.74 per share under a pre-arranged 10b5-1 plan.

Thermo Fisher Scientific's Senior VP and Chief HR Officer, Lisa P. Britt, disposed of common stock to cover tax withholding obligations.

Thermo Fisher Scientific Inc.'s Chairman and CEO, Marc N. Casper, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Thermo Fisher Scientific Chairman & CEO Marc N. Casper sold common stock shares totaling 496 shares on August 19-20, 2025, following the exercise of stock options, all under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific Inc. Chairman and CEO Marc N. Casper executed pre-planned stock option exercises and subsequent share sales.

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti sold 400 shares of common stock for $479.98 per share, executed under a Rule 10b5-1 trading plan.

Dion J. Weisler, a Director at Thermo Fisher Scientific Inc., acquired 91.85 phantom stock units as part of the company's Deferred Compensation Plan for Directors.

Scott M. Sperling, a Director at Thermo Fisher Scientific Inc., has acquired 102.35 phantom stock units as part of the company's Deferred Compensation Plan for Directors.

R. Alexandra Keith, a Director at Thermo Fisher Scientific Inc., acquired 76.54 phantom stock units through the company's Deferred Compensation Plan for Directors.

Karen S. Lynch, a Director at Thermo Fisher Scientific Inc., acquired 76.54 phantom stock units as part of the company's Deferred Compensation Plan for Directors.